PALO ALTO, Calif.—Tariq Musa, a director at Guardant Health , Inc. (NASDAQ:GH), recently sold a portion of his holdings in the company. According to a recent filing, Musa disposed of 116 shares of the company’s common stock at a price of $34.85 per share, totaling approximately $4,042. The transaction comes as the stock has experienced a notable 10.9% decline over the past week, according to InvestingPro data. Following this transaction, Musa retains ownership of 2,810 shares in the company. The sale was executed on December 18, 2024, and was reported to the Securities and Exchange Commission the following day. The company, currently valued at $3.87 billion, maintains strong liquidity with a current ratio of 6.22 and has achieved impressive revenue growth of 29.2% over the last twelve months. InvestingPro subscribers have access to 8 additional key insights and a comprehensive Pro Research Report, which provides detailed analysis of Guardant Health’s financial health, which is currently rated as GOOD.
In other recent news, Guardant Health, a precision oncology company, has revealed a collaboration with pharmaceutical firm Boehringer Ingelheim. The partnership aims to secure regulatory approval for Guardant360® CDx, a liquid biopsy test, as a companion diagnostic for zongertinib, an investigational drug for non-small cell lung cancer. Over the last twelve months, Guardant Health has seen a notable revenue growth of 29.2%.
The Guardant360 CDx test identifies patients with HER2 mutations in NSCLC who may benefit from zongertinib. This test is the first FDA-approved comprehensive liquid biopsy for all advanced solid tumors and has wide commercial and Medicare coverage. The collaboration is expected to facilitate oncologists in identifying advanced lung cancer patients suitable for treatment with zongertinib.
Guardant Health has also reported its financial results for the third quarter of 2024. While no specific financial details were disclosed, the absence of reported financial misses suggests that the company may have met its quarterly expectations. These recent developments highlight Guardant Health’s ongoing efforts to provide accurate financial reporting and transparency to its investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.